Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
08/2010
08/17/2010US7776343 comprising a negatively charged organic carrier and a positively charged antigen; for facilitating the induction of a cytotoxic T-lymphocyte response to an antigen
08/17/2010US7776342 Preparations that potentiate immunogenicity in low immunogenic antigens
08/17/2010US7776340 has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43
08/17/2010US7776335 Microorganismal enzymatic polypeptide for use in developing vaccine for prevention and treatment of nesserial infection
08/17/2010US7776325 Bactericide against Streptococcus mutans and Streptococcus sobrinus
08/17/2010CA2530216C The use of an edible acid or the potassium or sodium salt thereof in the treatment of allergy
08/17/2010CA2472372C Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
08/17/2010CA2471762C Cell-permeable peptide inhibitors of the jnk signal transduction pathway
08/17/2010CA2456453C Cc-1065 analog synthesis
08/17/2010CA2431974C Urea and urethane derivatives as integrin inhibitors
08/17/2010CA2411436C A method for detecting protein inhibitors and ligands
08/17/2010CA2397734C Water soluble prodrugs of azole compounds
08/17/2010CA2382940C 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
08/17/2010CA2352563C Method to produce inactivated w/o emulsion adjuvanted vaccines
08/17/2010CA2337828C Phosphinic and phosphonic acid derivatives used as pharmaceuticals
08/17/2010CA2290742C Use of galt-2 inhibitor compounds to treat conditions associated with lactosylceramide
08/17/2010CA2259707C Disinfecting and sterilizing concentrate containing an aromatic dialdehyde and a neutral ph buffering system
08/12/2010WO2010091386A2 Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
08/12/2010WO2010091280A1 N-halogenated amino acid formulations comprising phosphine or amine oxides
08/12/2010WO2010091131A1 Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
08/12/2010WO2010091124A2 Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
08/12/2010WO2010090860A2 Methods and compositions for treating bacterial infection
08/12/2010WO2010090707A2 A nef deleted human immunodeficiency virus for the restoration of t-lymphocyte signalling and activation for the treatment and prevention of human immunodeficiency virus infection
08/12/2010WO2010090654A1 Methods of reducing the proliferation and viability of microbial agents
08/12/2010WO2010090532A1 Compositions and dosage regimes comprising a clostridial vaccine and levamisole
08/12/2010WO2010089510A2 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
08/12/2010WO2010089379A1 Method and means for producing tissues and tissues obtained
08/12/2010WO2010089355A1 Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
08/12/2010WO2010089341A1 Novel vancomycin-aminoquinoline hybrid molecules their preparation and their application in therapeutics
08/12/2010WO2010088857A1 Crystal structure of amino terminal portion of influenza virus polymerase pa subunit and use thereof
08/12/2010WO2010088803A1 New porcine reproductive and respiratory syndrome virus receptor, and blockers thereof
08/12/2010WO2010059531A3 Alpha-keto peracids and methods for producing and using the same
08/12/2010WO2010054102A3 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
08/12/2010WO2010054042A3 Dimethylphenoxy modulators of viral protease activity and/or parasitic enzyme activity
08/12/2010WO2010039538A3 Flavivirus inhibitors and methods for their use
08/12/2010WO2010034974A3 Tuberculosis vaccines targeted to cd40
08/12/2010WO2010032043A3 Antimicrobial and/or anti-acne formulations containinga dialkyl sulphosuccinate or derivative thereof
08/12/2010WO2010030811A3 CARBACEPHEM β-LACTAM ANTIBIOTICS
08/12/2010WO2010030808A3 Novel antibiotics against resistant bacteria
08/12/2010WO2009143345A3 Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders
08/12/2010WO2009089534A3 Compositions and methods for the treatment of viral infections caused by influenza virus
08/12/2010US20100204337 Antibacterial s-heterosubstituted disulfides
08/12/2010US20100204326 Novel agents for treatment of ailments and dysfunctions
08/12/2010US20100204318 Treatment of virally induced lesions
08/12/2010US20100204316 Pseudopolymorphic forms of a hiv protease inhibitor
08/12/2010US20100204314 Drug for treatment of influenza
08/12/2010US20100204310 New modalities for treatment of drug-resistant tuberculosis and other diseases
08/12/2010US20100204302 Sidna against hepatitis c virus (hcv)
08/12/2010US20100204300 Anti-viral methods and compositions
08/12/2010US20100204297 Influenza therapeutic
08/12/2010US20100204293 Pharmaceutical composition
08/12/2010US20100204290 Procedure for operating a particle filter arranged in an exhaust fume area of a brennkraftmaschine and device to execute the procedure
08/12/2010US20100204271 Stable crystal of 4-oxoquinoline compound
08/12/2010US20100204270 Quinoline Derivatives as Antibacterial Agents
08/12/2010US20100204265 Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
08/12/2010US20100204260 synthesis of new class of nonsteroidal antiinflammatory and antibacterial agent for use treating septic shock, asthma, arthritis, cancer; e.g. 1-Benzyl-2,4,5-triphenyl-4,5-dihydro-1H-imidazole-4-carboxylic acid
08/12/2010US20100204253 Ribosome Structure and Protein Synthesis Inhibitors
08/12/2010US20100204243 Process for the Preparation of Poly DL-Lactide-Co-Glycolide Nanoparticles Having Antitubercular Drugs Encapsulated Therein
08/12/2010US20100204226 Quinazolinones as prolyl hydroxylase inhibitors
08/12/2010US20100204217 Treatment for leukemia and idiopathic aplastic anemia
08/12/2010US20100204213 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
08/12/2010US20100204212 Fused heterocyclic compounds useful as kinase modulators
08/12/2010US20100204201 Hiv integrase inhibitors
08/12/2010US20100204191 Function-Selective Vitamin D Receptor Agonist
08/12/2010US20100204186 Aromatic a-ring derivatives of tetracycline compounds
08/12/2010US20100204184 Phosphonates useful as modulators of T-gamma-9-delta-2 activity
08/12/2010US20100204179 Resveratrol complex and process for the preperation
08/12/2010US20100204173 Methods of treating hepatic encephalopathy
08/12/2010US20100204161 Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria
08/12/2010US20100204159 Organic compounds and their uses
08/12/2010US20100204157 Use of a peptide as a therapeutic agent
08/12/2010US20100204155 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
08/12/2010US20100204154 Use of the peptide rfmwmr as a therapeutic agent
08/12/2010US20100204153 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
08/12/2010US20100204151 Use of a peptide as a therapeutic agent
08/12/2010US20100204150 Use of a peptide as a therapeutic agent
08/12/2010US20100204149 Use of octreotide as a therapeutic agent
08/12/2010US20100204148 (d-leu7 ) -histrelin as a therapeutic agent
08/12/2010US20100204145 Use of a peptide as a therapeutic agent
08/12/2010US20100204144 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
08/12/2010US20100204143 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
08/12/2010US20100204142 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
08/12/2010US20100204141 Use of bpp-b as a therapeutic agent
08/12/2010US20100204140 Use of a peptide as a therapeutic agent
08/12/2010US20100204139 Use of gonadorelin as a therapeutic agent
08/12/2010US20100204136 Use of a peptide as a therapeutic agent
08/12/2010US20100204135 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
08/12/2010US20100204134 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent
08/12/2010US20100204133 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating HIV
08/12/2010US20100204130 Use of human neuropeptide as a therapeutic agent
08/12/2010US20100204129 Use of a peptide as a therapeutic agent
08/12/2010US20100204120 Trimeric hiv fusion inhibitors for treating or preventing hiv infection
08/12/2010US20100204118 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
08/12/2010US20100204113 Use of stresscopin-related peptide as a therapeutic agent
08/12/2010US20100204111 Astressin and beta- endorphin for use as therapeutic agents
08/12/2010US20100204110 Use of a peptide as a therapeutic agent
08/12/2010US20100204109 Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
08/12/2010US20100204108 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
08/12/2010US20100204107 Use of urodilatin as a therapeutic agent
08/12/2010US20100204098 Peptides with antifungal activity
1 ... 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 ... 1798